Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

10.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
10.7K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma.

Blood advances·2026
Same author

A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.

Leukemia·2026
Same author

Long-Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators.

American journal of hematology·2026
Same author

Atmospheric mercury monitoring data across Italy: A multi-year national dataset (2020 - 2023).

Data in brief·2026
Same author

AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.

Blood advances·2026
Same author

Paraneoplastic Neuro-Ophthalmologic Symptoms as Initial Manifestation of Hodgkin Lymphoma.

Hematology reports·2026

Related Experiment Video

Updated: Oct 15, 2025

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.0K

[Lymphoid malignancy diagnostics].

Judit Jørgensen, Peter Kamper, Francesco d'Amore1

  • 1frandamo@rm.dk.

Ugeskrift for Laeger
|October 28, 2021
PubMed
Summary

The 2016 WHO classification update for lymphoid malignancies introduces new entities and treatments. Advances in understanding pathogenesis and precision medicine are improving lymphoma patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • The World Health Organization (WHO) classification of lymphoid malignancies is periodically updated to reflect advances in understanding these diseases.
  • The 2016 update incorporated new entities and modifications impacting diagnostic and therapeutic approaches.
  • Lymphoid malignancies are complex diseases driven by genetic, epigenetic, and microenvironmental factors.

Purpose of the Study:

  • To review the key changes in the 2016 WHO classification of lymphoid malignancies.
  • To discuss the implications of these updates on current treatment paradigms.
  • To highlight emerging interventional strategies and novel therapeutic agents.

Main Methods:

  • Review of the literature pertaining to the 2016 WHO classification update.

More Related Videos

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

12.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.2K

Related Experiment Videos

Last Updated: Oct 15, 2025

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.0K
Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

12.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.2K
  • Analysis of pathogenetic mechanisms including surface markers, signaling pathways, and the tumor microenvironment.
  • Evaluation of novel agents and immune therapeutic strategies.

    • Main Results:

    • The 2016 WHO update introduced new classifications and modified existing ones for lymphoid neoplasms.
    • Increased understanding of molecular pathogenesis has led to the development of targeted therapies and immunotherapies.
    • Precision medicine approaches are demonstrating improved clinical responses and patient prognoses.

    Conclusions:

    • The 2016 WHO classification provides a crucial framework for diagnosing and managing lymphoid malignancies.
    • Advances in understanding disease mechanisms are driving the development of more effective and personalized treatments.
    • Reliable assessment of clinical response quality is essential for evaluating treatment efficacy and improving patient outcomes.